Assessing measles risk transmission in Iran: a utilization of the World Health Organization's programmatic risk assessment tool,2022.
Iran
Measles transmission
Risk assessment
Risk assessment tool
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
05 Oct 2024
05 Oct 2024
Historique:
received:
31
03
2024
accepted:
28
08
2024
medline:
6
10
2024
pubmed:
6
10
2024
entrez:
5
10
2024
Statut:
epublish
Résumé
Despite successful efforts to eliminate measles in Iran, imported measles cases continue to be reported. Because measles is endemic in neighboring countries. This research aims to evaluate the risk of measles transmission in different regions of Iran. Measles case-based surveillance data of the Expanded Program of Immunization containing 31 provinces and 463 districts from 2019 to 2021 were assessed. The WHO Measles Programmatic Risk Assessment tool was used to evaluate the risk of disease transmission in four domains: population immunity, surveillance quality, program delivery performance, and threat assessment. scores were categorized as low, medium, high, or very high risk. During 2019-2021, the average incidence of measles was 1.9 per 1 million. Chabahar and Mashhad with 76 and ./6per million reported the highest and lowest incidence respectively. All 463 districts were categorized as low risk in risk assessment. Andimeshk, Chabahar, and Bojnurd obtained the highest risk scores with 27, 24, and 25 respectively. All districts were classified as low risk for population immunity. The average coverage of (MMR1) and (MMR2) was 95% or higher. All districts received the minimum points for surveillance quality. All regions are placed at a low level of disease transmission risk. However, the tool is not able to assess the risk at the rural or peripheral sectors level. The indicators used in this tool are the same for all countries with different epidemiological features (elimination, endemic). Sensitivity analysis can optimize the use of this tool for countries with different disease conditions.
Sections du résumé
BACKGROUND
BACKGROUND
Despite successful efforts to eliminate measles in Iran, imported measles cases continue to be reported. Because measles is endemic in neighboring countries. This research aims to evaluate the risk of measles transmission in different regions of Iran.
METHODS
METHODS
Measles case-based surveillance data of the Expanded Program of Immunization containing 31 provinces and 463 districts from 2019 to 2021 were assessed. The WHO Measles Programmatic Risk Assessment tool was used to evaluate the risk of disease transmission in four domains: population immunity, surveillance quality, program delivery performance, and threat assessment. scores were categorized as low, medium, high, or very high risk.
RESULTS
RESULTS
During 2019-2021, the average incidence of measles was 1.9 per 1 million. Chabahar and Mashhad with 76 and ./6per million reported the highest and lowest incidence respectively. All 463 districts were categorized as low risk in risk assessment. Andimeshk, Chabahar, and Bojnurd obtained the highest risk scores with 27, 24, and 25 respectively. All districts were classified as low risk for population immunity. The average coverage of (MMR1) and (MMR2) was 95% or higher. All districts received the minimum points for surveillance quality.
CONCLUSION
CONCLUSIONS
All regions are placed at a low level of disease transmission risk. However, the tool is not able to assess the risk at the rural or peripheral sectors level. The indicators used in this tool are the same for all countries with different epidemiological features (elimination, endemic). Sensitivity analysis can optimize the use of this tool for countries with different disease conditions.
Identifiants
pubmed: 39369223
doi: 10.1186/s12879-024-09834-8
pii: 10.1186/s12879-024-09834-8
doi:
Substances chimiques
Measles Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1108Informations de copyright
© 2024. The Author(s).
Références
Hübschen JM, Gouandjika-Vasilache I, Dina J. Measles. Lancet. 2022;399(10325):678–90.
doi: 10.1016/S0140-6736(21)02004-3
pubmed: 35093206
Chen HL, Tang RB. Measles re-emerges and recommendation of vaccination. J Chin Med Assoc. 2020;83(1):5–7.
doi: 10.1097/JCMA.0000000000000210
pubmed: 31569091
Crecelius EM, Burnett MW. Measles (Rubeola): an update. J Spec Oper Med. 2020;20(2):136–8.
doi: 10.55460/3NFC-341T
pubmed: 32573751
Gastanaduy PA, Goodson JL, Panagiotakopoulos L, Rota PA, Orenstein WA, Patel M. Measles in the 21st century: progress toward achieving and sustaining elimination. J Infect Dis. 2021;224(12 Suppl 2):S420-8.
doi: 10.1093/infdis/jiaa793
pubmed: 34590128
pmcid: 8482021
measles 2023 [cited 2023 2023]. Available from: https://www.who.int/health- .
Henao-Restrepo AM, Strebel P, John Hoekstra E, Birmingham M, Bilous J. Experience in global measles control, 1990–2001. J Infect Dis. 2003;187(Supplement1):S15–21.
doi: 10.1086/368273
pubmed: 12721887
Davoodian P, Atashabparvar A, Dadvand H, Hosseinpour M, Daryanavard A, Safari R, et al. A report of outbreaks of measles on the southern coast of Iran from 2009 to 2015. Electron Physician. 2017;9(3):3997–4002.
doi: 10.19082/3997
pubmed: 28461876
pmcid: 5407234
Rejali M, Mohammadbeigi A, Mokhtari M, Zahraei SM, Eshrati B. Timing and delay in children vaccination; evaluation of expanded program of immunization in outskirt of Iranian cities. J Res Health Sci. 2015;15(1):54–8.
pubmed: 25821027
World Health Organization (WHO), Measles Programmatic Risk Assessment Tool. 2017. URL: 2022. [Available from: http://www.who.int/entity/immunization/monitoring .
Zahraei SM, Gouya MM, Mohammadi M, Tabatabaei SM, Zanganeh M, Zareban I, Kiani M, Adineh HA, Sabouri A, Ansari-Moghaddam A, Elhami FM. A survey on measles and rubella supplementary immunization activities (SIAs) in Iran. Health Scope. 2017;6(4).
Hosseinalipour SA, Mohammadbeigi A, Mohebi S, Saghafipour A, Arabshahi A, Mahdianpour F. Measles Elimination successful and its relevant challenges in Iran. Int J Prev Med. 2022;13:52.
doi: 10.4103/ijpvm.IJPVM_334_20
pubmed: 35706857
pmcid: 9188879
Alimohamadi Y, Sepandi M. Forty-seven year trend of measles in Iran: an interrupted time series analysis. Health Sci Rep. 2023;6(2):e1139.
doi: 10.1002/hsr2.1139
pubmed: 36852390
pmcid: 9957696
https://www.who.int/news/item/23-11-2022-nearly-40-million-children-are-dangerously-susceptible-to-growing-measles-threat#:~:text=growing%20measles%20threat-,Nearly%2040%20million%20children%20are%20dangerously%20susceptible%20to%20growing%20measles%20threat,Joint%20News%20Release,-Reading%20time%3A . 23 November 2022.
Lam E, Schluter WW, Masresha BG, Teleb N, Bravo-Alcántara P, Shefer A, et al. Development of a district-level programmatic assessment tool for risk of measles virus transmission. Risk Anal. 2017;37(6):1052–62.
doi: 10.1111/risa.12409
pubmed: 25976980
Kriss JL, Stanescu A, Pistol A, Butu C, Goodson JL. The World Health Organization Measles Programmatic Risk Assessment Tool-Romania, 2015. Risk Anal. 2017;37(6):1096–107.
doi: 10.1111/risa.12669
pubmed: 27439071
Kriss JL, De Wee RJ, Lam E, Kaiser R, Shibeshi ME, Ndevaetela EE, et al. Development of the World Health Organization Measles Programmatic Risk Assessment Tool using experience from the 2009 Measles Outbreak in Namibia. Risk Anal. 2017;37(6):1072–81.
doi: 10.1111/risa.12544
pubmed: 26895314
Mohammadbeigi A, Zahraei SM, Asgarian A, Afrashteh S, Mohammadsalehi N, Khazaei S, et al. Estimation of measles risk using the World Health Organization Measles Programmatic Risk Assessment Tool, Iran. Heliyon. 2018;4(11):e00886.
doi: 10.1016/j.heliyon.2018.e00886
pubmed: 30417154
pmcid: 6218648
Ducusin MJU, de Quiroz-Castro M, Roesel S, Garcia LC, Cecilio‐Elfa D, Schluter WW, et al. Using the World Health Organization measles programmatic risk assessment tool for monitoring of supplemental immunization activities in the Philippines. Risk Anal. 2017;37(6):1082–95.
doi: 10.1111/risa.12404
pubmed: 25950923
Measles - number of reported. cases 2023-07-11. [Available from: https://www.who.int/data/gho/data/indicators/indicator-details/GHO/measles---number-of-reported-cases .
Zahraei SM, Mohammadbeigi A, Mohammadsalehi N, Sabouri A, Afrashteh S, Jang SA, et al. Monitoring of surveillance quality indicators of measles in Iranian districts: analysis of measles surveillance system 2014–2016. J Res Health Sci. 2018;18(3):e00418.
pubmed: 30270213
pmcid: 6941647
Goel K, Naithani S, Bhatt D, Khera A, Sharapov UM, Kriss JL, et al. The World Health Organization Measles Programmatic Risk Assessment Tool-Pilot Testing in India, 2014. Risk Anal. 2017;37(6):1063–71.
doi: 10.1111/risa.12615
pubmed: 27088758
Gallegos D, Vergara N, Gatica L, Castillo C, Basaldúa A, Guerrero R, et al. [Risk matrix for estimating imported outbreaks of measles or rubella in ChileMatriz De risco para estimar surtos importados de sarampo ou rubéola aplicada ao Chile]. Rev Panam Salud Publica. 2017;41:e47.
pubmed: 31363357
pmcid: 6612727
Karami MZS, Sabouri A, Soltanshahi R, Biderafsh A, Piri N, et al. Documentation of research in health sciences measles elimination in Iran:. 2012 to 2014. J Res Health Sci. 2017;17(3):387.
pmcid: 7189955
Izadi S, Shahmahmoodi S, Zahraei SM, Dorostkar F, Majdzadeh R. Risk of polio reintroduction to border regions of Islamic Republic of Iran: seroprevalence study of children with at least 5 doses of oral polio vaccine. 2014.
Mohammadbeigi A, Zahraei SM, Sabouri A, Asgarian A, Afrashteh S, Ansari H. The spatial analysis of annual measles incidence and transition threat assessment in Iran in 2016. Med J Islam Repub Iran. 2019;33:130.
pubmed: 32280636
pmcid: 7137842